Received Sep 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLUN3 | INFLUENZA (SEASONAL) (FLUMIST) | MEDIMMUNE VACCINES, INC. | UNK | — | OT |
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | 1 | — | OT |
administration of extra dose of ipol with no reported ae; supposed to receive the flumist however, he and his 6-year-old brother switched places in the grandma's lap, so when she turned around, the 6-year-old brother was given with ipol with no reported ae; Initial information received on 24-Sep-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 6 years old male patient who had administration of extra dose of IPV (Vero) [IPOL] and supposed to receive the flumist however, he and his 6-year-old brother switched places in the grandma's lap, so when she turned around with no reported ae (adverse event) The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose 5 of suspect IPV (VERO) Suspension for injection via unknown route in unknown administration site and 4 other doses were administered on unknown dates for suspect IPV (VERO) (strength, expiry date and lot number not reported for all regimens) for prophylactic vaccination (immunization) instead of flumist with no reported ae (extra dose administered) (wrong product administered) (same day latency). Information regarding batch number and expiration date corresponding to the one at time of event occurrence was requested. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.